Bryan M Burt1, William G Richards2, Hyun-Sung Lee1, Sylvia Bartel3, Marcelo C Dasilva2, Ritu R Gill4, Michael T Jaklitsch2, Bruce E Johnson5, Scott J Swanson2, Raphael Bueno2, David J Sugarbaker6. 1. Department of Surgery, Division of General Thoracic Surgery, Baylor College of Medicine, Houston, Texas. 2. Department of Surgery, Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts. 3. Research Pharmacy Core, Pharmacy and Clinical Support, Dana-Farber Cancer Institute, Boston, Massachusetts. 4. Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 5. Cancer Center, Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 6. Department of Surgery, Division of General Thoracic Surgery, Baylor College of Medicine, Houston, Texas. Electronic address: David.Sugarbaker@bcm.edu.
Abstract
INTRODUCTION: The primary objective of this single-institution phase I clinical trial was to establish the maximum tolerated dose of gemcitabine added to cisplatin and delivered as heated intraoperative chemotherapy after resection of malignant pleural mesothelioma. METHODS: The extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D) treatment arms were based on investigators' assessment of patient fitness and potential for macroscopic complete resection. Previously established intracavitary dosing of cisplatin (range 175-225 mg/m2) with systemic cytoprotection was used in combination with escalating doses of gemcitabine, following a 3-plus-3 design from 100 mg/m2 in 100-mg increments. RESULTS: From 2007 to 2011, 141 patients were enrolled and 104 completed treatment. The median age of those completing treatment was 65 years (range 43-85 years), and 22 (21%) were female. In the EPP arm (n = 59), 31 patients (53%) had the epithelioid histologic type and the median radiographic tumor volume was 236 cm3 (range 16-4285 cm3). In the P/D arm (n = 41), 29 patients (71%) had the epithelioid histologic type and the median tumor volume was 79 cm3 (range 6-1107 cm3). The operative mortality rate was 2%, and 35 and 22 serious adverse events were encountered among 27 patients (46%) and 16 patients (39%) in the EPP and P/D arms, respectively. Dose-limiting toxicity (grade 3 leukopenia) was observed in two patients who were receiving 1100 mg/m2 of gemcitabine, thus establishing the maximum tolerated dose at 1000 mg/m2, in combination with 175 mg/m2 of cisplatin. The median overall and recurrence-free survival times in treated patients were 20.3 and 10.7 months, respectively. CONCLUSIONS: Combination cisplatin and gemcitabine heated intraoperative chemotherapy can be administered safely and feasibly in the context of complete surgical resection of malignant pleural mesothelioma by EPP or P/D.
INTRODUCTION: The primary objective of this single-institution phase I clinical trial was to establish the maximum tolerated dose of gemcitabine added to cisplatin and delivered as heated intraoperative chemotherapy after resection of malignant pleural mesothelioma. METHODS: The extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D) treatment arms were based on investigators' assessment of patientfitness and potential for macroscopic complete resection. Previously established intracavitary dosing of cisplatin (range 175-225 mg/m2) with systemic cytoprotection was used in combination with escalating doses of gemcitabine, following a 3-plus-3 design from 100 mg/m2 in 100-mg increments. RESULTS: From 2007 to 2011, 141 patients were enrolled and 104 completed treatment. The median age of those completing treatment was 65 years (range 43-85 years), and 22 (21%) were female. In the EPP arm (n = 59), 31 patients (53%) had the epithelioid histologic type and the median radiographic tumor volume was 236 cm3 (range 16-4285 cm3). In the P/D arm (n = 41), 29 patients (71%) had the epithelioid histologic type and the median tumor volume was 79 cm3 (range 6-1107 cm3). The operative mortality rate was 2%, and 35 and 22 serious adverse events were encountered among 27 patients (46%) and 16 patients (39%) in the EPP and P/D arms, respectively. Dose-limiting toxicity (grade 3 leukopenia) was observed in two patients who were receiving 1100 mg/m2 of gemcitabine, thus establishing the maximum tolerated dose at 1000 mg/m2, in combination with 175 mg/m2 of cisplatin. The median overall and recurrence-free survival times in treated patients were 20.3 and 10.7 months, respectively. CONCLUSIONS: Combination cisplatin and gemcitabine heated intraoperative chemotherapy can be administered safely and feasibly in the context of complete surgical resection of malignant pleural mesothelioma by EPP or P/D.
Authors: Marcello Migliore; Michael Ried; Laureano Molins; Marco Lucchi; Marcello Ambrogi; Tamas F Molnar; Hans-Stefan Hofmann Journal: Ann Transl Med Date: 2021-06
Authors: Giovanna Li Petri; Btissame El Hassouni; Rocco Sciarrillo; Niccola Funel; Giulia Mantini; Eveline A Zeeuw van der Laan; Stella Cascioferro; Amir Avan; Paolo Andrea Zucali; Nadia Zaffaroni; Tonny Lagerweij; Barbara Parrino; Kees Smid; Marcello Deraco; Carlotta Granchi; Alicja Braczko; Ryszard T Smolenski; Larry H Matherly; Gerrit Jansen; Yehuda G Assaraf; Patrizia Diana; Jacqueline Cloos; Godefridus J Peters; Filippo Minutolo; Elisa Giovannetti Journal: Br J Cancer Date: 2020-06-04 Impact factor: 7.640
Authors: Christopher Larisch; Till Markowiak; Elena Loch; Christian Großer; Patrick J Bednarski; Karolina Mueller; Hans-Stefan Hofmann; Michael Ried Journal: Ann Transl Med Date: 2021-06
Authors: Till Markowiak; Michael Koller; Florian Zeman; Gunnar Huppertz; Hans-Stefan Hofmann; Michael Ried Journal: BMJ Open Date: 2020-07-20 Impact factor: 2.692